🔗 Share this article Individuals Coming Off Weight-Loss Medications Regain Weight Four Times Faster Than People Using Diet and Exercise Weight management often requires ongoing approaches. New research reveals that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop conventional lifestyle plans. Research printed in a prominent health publication points out that while obese individuals often shed a large proportion of their body weight while using the jabs, the mass returns at an average rate of 0.8 kg per month after stopping. "Users buying such medications should be informed of the potential of quick weight regain when the medication concludes," warns expert Dr. Susan Jebb. Such speed of regain suggests a return to original weight within about 18 months. Analyzing Approaches The analysis, which reviewed dozens of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods. Researchers emphasize that individuals who lose weight through lifestyle changes alone typically experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish. Understanding the Rapid Rebound Experts suggest the mechanism of the drugs explains the amplified rebound. These medications mimic a body's own chemical called GLP-1, which moderates feelings of fullness. "Long-term administration of the hormone concentrations several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition expert. "Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making excessive eating a significant risk." A Lifelong Condition? Medical guidelines recommend the injections for individuals with obesity-related health risks, alongside prescribed lifestyle changes. Many experts say that, due to the significant potential of weight regain, the therapy is often ongoing. This view is supported by pharmaceutical companies, who state that the findings "highlight the chronic nature of obesity," comparing it to managing diseases like hypertension. Patient Experiences Users who have come off the medication describe a intense resurgence of hunger. "It was like something flipping and you become starving," recalled one woman. This challenge is exacerbated if patients have not developed sustainable lifestyle or habit modifications during treatment. Widespread Interest Figures suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with demand being substantial. Adoption is greater among women compared to males. The middle-aged demographic shows the greatest usage rates. A large proportion obtain the medications through private prescriptions rather than the NHS. In conclusion, researchers emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on ongoing behavioural changes.
Weight management often requires ongoing approaches. New research reveals that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop conventional lifestyle plans. Research printed in a prominent health publication points out that while obese individuals often shed a large proportion of their body weight while using the jabs, the mass returns at an average rate of 0.8 kg per month after stopping. "Users buying such medications should be informed of the potential of quick weight regain when the medication concludes," warns expert Dr. Susan Jebb. Such speed of regain suggests a return to original weight within about 18 months. Analyzing Approaches The analysis, which reviewed dozens of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods. Researchers emphasize that individuals who lose weight through lifestyle changes alone typically experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish. Understanding the Rapid Rebound Experts suggest the mechanism of the drugs explains the amplified rebound. These medications mimic a body's own chemical called GLP-1, which moderates feelings of fullness. "Long-term administration of the hormone concentrations several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition expert. "Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making excessive eating a significant risk." A Lifelong Condition? Medical guidelines recommend the injections for individuals with obesity-related health risks, alongside prescribed lifestyle changes. Many experts say that, due to the significant potential of weight regain, the therapy is often ongoing. This view is supported by pharmaceutical companies, who state that the findings "highlight the chronic nature of obesity," comparing it to managing diseases like hypertension. Patient Experiences Users who have come off the medication describe a intense resurgence of hunger. "It was like something flipping and you become starving," recalled one woman. This challenge is exacerbated if patients have not developed sustainable lifestyle or habit modifications during treatment. Widespread Interest Figures suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with demand being substantial. Adoption is greater among women compared to males. The middle-aged demographic shows the greatest usage rates. A large proportion obtain the medications through private prescriptions rather than the NHS. In conclusion, researchers emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on ongoing behavioural changes.